# Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

> **NCT04961359** · PHASE1 · COMPLETED · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 75 (actual)

## Conditions studied

- Coronavirus

## Interventions

- **BIOLOGICAL:** Recombinant new coronavirus vaccine (CHO cell) group
- **BIOLOGICAL:** Recombinant new coronavirus vaccine (CHO cells) placebo group

## Key facts

- **NCT ID:** NCT04961359
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-03
- **Primary completion:** 2021-12-12
- **Final completion:** 2023-04-06
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04961359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04961359, "Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04961359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*